WaveMan
WaveMan · Company
IVVD · Invivyd, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IVVD Invivyd (IVVD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001832038
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
73
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed

What the filings say about IVVD

Insiders, 180 days
-$177.1K net sold
5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$164.5K
5 notices

Invivyd insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Invivyd, Inc. insiders sold a net $177.1K of stock across 48 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lee Timothy Edward
Chief Commercial Officer
SELL
2026-08-18 SEC
18,425
$15.5K
-38.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 17, 2026.
  • The trade is 10.3% of the 178,937 shares held after it.
  • 4 other insiders sold within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Lee Timothy Edward sold about $15.5K of IVVD on Aug 18, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.
Green Julie
Chief Human Resources Officer
SELL
2026-08-18 SEC
18,425
$15.5K
-38.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 17, 2026.
  • The trade is 10.9% of the 168,937 shares held after it.
  • 4 other insiders sold within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Human Resources Officer Green Julie sold about $15.5K of IVVD on Aug 18, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.
Duke William E.
Chief Financial Officer
SELL
2026-08-18 SEC
18,425
$15.5K
-38.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 17, 2026.
  • The trade is 10.9% of the 168,937 shares held after it.
  • 4 other insiders sold within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Duke William E. sold about $15.5K of IVVD on Aug 18, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.
Andersen Jill
Chief Legal Officer, Secretary
SELL
2026-08-18 SEC
30,706
$25.9K
-38.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 17, 2026.
  • The trade is 10.8% of the 283,774 shares held after it.
  • 4 other insiders sold within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer, Secretary Andersen Jill sold about $25.9K of IVVD on Aug 18, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.
Allen Robert D. III
Chief Scientific Officer
SELL
2026-08-18 SEC
17,043
$14.4K
-38.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 17, 2026.
  • The trade is 9.5% of the 178,765 shares held after it.
  • 4 other insiders sold within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Allen Robert D. III sold about $14.4K of IVVD on Aug 18, 2026; 4 other insiders sold within 30 days and 73 funds added in the latest 13F quarter.
48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 43 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$177.1K over 180 days
-$177.1K over 90 days
more than 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
73 funds bought in last quarter
more than 57% of Pharma & Biotech
Revenue
+110.5% year over year
more than 85% of Pharma & Biotech
Margin
-98.2% net margin
below 57% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.8% of the float short (float per yahoo 2026-10-27) · 6.9 days to cover · settled 2026-10-15
more than 80% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IVVD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-69.6%12M
-72%-32%+8%+48%2025-102025-122026-022026-042026-062026-082026-10 2025-11-19 · MCLAUGHLIN KEVIN F bought $125.0K2026-02-18 · Andersen Jill sold $55.2K2026-02-17 · Andersen Jill sold $50.5K2026-02-18 · Green Julie sold $33.1K2026-02-18 · Duke William E. sold $33.1K2026-02-18 · Lee Timothy Edward sold $33.1K2026-02-18 · Allen Robert D. III sold $30.6K2026-02-17 · Green Julie sold $30.3K2026-02-17 · Duke William E. sold $30.3K2026-02-17 · Lee Timothy Edward sold $30.3K2026-02-17 · Allen Robert D. III sold $28.0K2026-08-17 · Andersen Jill sold $26.9K2026-08-18 · Andersen Jill sold $25.9K2026-08-17 · Lee Timothy Edward sold $16.1K2026-08-17 · Green Julie sold $16.1K2026-08-17 · Duke William E. sold $16.1K2026-08-18 · Lee Timothy Edward sold $15.5K2026-08-18 · Green Julie sold $15.5K2026-08-18 · Duke William E. sold $15.5K2026-08-17 · Allen Robert D. III sold $14.9K2026-08-18 · Allen Robert D. III sold $14.4K2026-08-17 · Allen Robert D. III filed to sell $27.2K2026-08-17 · Andersen Jill filed to sell $49.0K2026-08-17 · Duke William E. filed to sell $29.4K2026-08-17 · Green Julie filed to sell $29.4K2026-08-17 · Lee Timothy Edward filed to sell $29.4K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IVVD: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
34,173,104 sh
$30.0M
BVF INC/IL
28,165,000 sh
$24.6M
MAVERICK CAPITAL LTD
18,970,913 sh
$16.6M
PERCEPTIVE ADVISORS LLC
18,490,636 sh
$16.1M
BlackRock, Inc.
16,134,885 sh
$14.1M

Congress trades in IVVD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IVVD planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Allen Robert D. III
Filed 2026-08-17
$27.2K
Andersen Jill
Filed 2026-08-17
$49.0K
Duke William E.
Filed 2026-08-17
$29.4K
Green Julie
Filed 2026-08-17
$29.4K
Lee Timothy Edward
Filed 2026-08-17
$29.4K

IVVD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$216.0K position · as of 2026-07-31
0.5%
Ultra-Small Company Market Fund
$81.5K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$616.3K position · as of 2026-06-30
0.0%
Invesco Nasdaq Biotechnology ETF
$16.7K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$41.4K position · as of 2026-06-30
0.0%
ProShares Ultra Nasdaq Biotechnology
$11.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
1
Phase 2
1 active
3
Phase 3
1 active
1
Not applicable
0 active
2
Multi-phase
0 active
What changed recently
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, a
2026-10-15 · Completion moved 2026-08 → 2026-08-15
Phase 3
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, a
2026-10-15 · Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $177.1K sold by insiders over 180 days, 73 funds added last quarter, $164.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IVVD financials

Revenue growth
+110.5%
XBRL, annual
Net margin
-98.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$58.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-183.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$109.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-95.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-69.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-96.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-63.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$53.4M$25.4M$0n/a
Operating income-$55.6M-$176.9M-$212.8M-$248.0M
Net income-$52.5M-$169.9M-$198.6M-$241.3M
EPS (diluted)-0.30-1.43-1.81-2.23
Operating cash flow-$58.1M-$170.5M-$173.2M-$220.0M
Cash$226.7M$69.3M$200.6M$92.1M
Buybacksn/a$0$1.0K$4.0K
SEC XBRL, fiscal years, as known on 2026-10-28

IVVD Stock Sonar score 5/7 axes

Find similar shapesCompare

IVVD ranks highest on growth (85th percentile) and institutional and government (58th), and lowest on insider conviction (25th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
32
Inputs
  • Return on equity-95.9% · 34 pct, sector of 545
  • Return on assets-69.7% · 34 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-96.8% · 26 pct, sector of 576
Growth
85
Inputs
  • Revenue growth, YoY+110.5% · 85 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
25
Inputs
  • Net Form 4 buying (codes P and S), 180d-$177K · 49 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
58
Inputs
  • Funds adding, latest quarter73 · 57 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$340K · 60 pct, sector of 133
Risk and compliance
39
Inputs
  • Short interest, % of float+17.8% · 18 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.9% · 59 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IVVD filings, in plain words

Are Invivyd insiders buying or selling IVVD?

In the 180 days to 2026-10-28, Invivyd insiders were net sellers, a net $177.1K across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of IVVD?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $164.5K of stock; the latest, by Allen Robert D. III, was filed 2026-08-17.

Read the full summary

In the 180 days to 2026-10-28, Invivyd insiders were net sellers of IVVD, a net $177.1K across purchases and sales reported on Form 4 by 5 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $164.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies